Transplantation outcomes in patients with primary hyperoxaluria: a systematic review.
CKLT
Primary hyperoxaluria
SKLT
graft survival
kidney transplantation
liver transplantation
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
28
11
2020
accepted:
03
03
2021
revised:
16
02
2021
pubmed:
9
4
2021
medline:
27
1
2022
entrez:
8
4
2021
Statut:
ppublish
Résumé
Primary hyperoxaluria type 1 (PH1) is characterized by hepatic overproduction of oxalate and often results in kidney failure. Liver-kidney transplantation is recommended, either combined (CLKT) or sequentially performed (SLKT). The merits of SLKT and the place of an isolated kidney transplant (KT) in selected patients are unsettled. We systematically reviewed the literature focusing on patient and graft survival rates in relation to the chosen transplant strategy. We searched MEDLINE and Embase using a broad search string, consisting of the terms 'transplantation' and 'hyperoxaluria'. Studies reporting on at least four transplanted patients were selected for quality assessment and data extraction. We found 51 observational studies from 1975 to 2020, covering 756 CLKT, 405 KT and 89 SLKT, and 51 pre-emptive liver transplantations (PLT). Meta-analysis was impossible due to reported survival probabilities with varying follow-up. Two individual high-quality studies showed an evident kidney graft survival advantage for CLKT versus KT (87% vs. 14% at 15 years, p<0.05) with adjusted HR for graft failure of 0.14 (95% confidence interval: 0.05-0.41), while patient survival was similar. Three other high-quality studies reported 5-year kidney graft survival rates of 48-89% for CLKT and 14-45% for KT. PLT and SLKT yielded 1-year patient and graft survival rates up to 100% in small cohorts. Our study suggests that CLKT leads to superior kidney graft survival compared to KT. However, evidence for merits of SLKT or for KT in pyridoxine-responsive patients was scarce, which warrants further studies, ideally using data from a large international registry.
Sections du résumé
BACKGROUND
Primary hyperoxaluria type 1 (PH1) is characterized by hepatic overproduction of oxalate and often results in kidney failure. Liver-kidney transplantation is recommended, either combined (CLKT) or sequentially performed (SLKT). The merits of SLKT and the place of an isolated kidney transplant (KT) in selected patients are unsettled. We systematically reviewed the literature focusing on patient and graft survival rates in relation to the chosen transplant strategy.
METHODS
We searched MEDLINE and Embase using a broad search string, consisting of the terms 'transplantation' and 'hyperoxaluria'. Studies reporting on at least four transplanted patients were selected for quality assessment and data extraction.
RESULTS
We found 51 observational studies from 1975 to 2020, covering 756 CLKT, 405 KT and 89 SLKT, and 51 pre-emptive liver transplantations (PLT). Meta-analysis was impossible due to reported survival probabilities with varying follow-up. Two individual high-quality studies showed an evident kidney graft survival advantage for CLKT versus KT (87% vs. 14% at 15 years, p<0.05) with adjusted HR for graft failure of 0.14 (95% confidence interval: 0.05-0.41), while patient survival was similar. Three other high-quality studies reported 5-year kidney graft survival rates of 48-89% for CLKT and 14-45% for KT. PLT and SLKT yielded 1-year patient and graft survival rates up to 100% in small cohorts.
CONCLUSIONS
Our study suggests that CLKT leads to superior kidney graft survival compared to KT. However, evidence for merits of SLKT or for KT in pyridoxine-responsive patients was scarce, which warrants further studies, ideally using data from a large international registry.
Identifiants
pubmed: 33830344
doi: 10.1007/s00467-021-05043-6
pii: 10.1007/s00467-021-05043-6
pmc: PMC8260423
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2217-2226Références
Hoppe B (2012) An update on primary hyperoxaluria. Nat Rev Nephrol 8:467–475. https://doi.org/10.1038/nrneph.2012.113
doi: 10.1038/nrneph.2012.113
pubmed: 22688746
Fargue S (2014) Factors influencing clinical outcome in patients with primary hyperoxaluria type 1. Kidney Int 86:1074–1076. https://doi.org/10.1038/ki.2014.280
doi: 10.1038/ki.2014.280
pubmed: 25427081
Mandrile G, van Woerden CS, Berchialla P, Beck BB, Acquaviva Bourdain C, Hulton SA, Rumsby G, OxalEurope Consortium (2014) Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int 86:1197–1204. https://doi.org/10.1038/ki.2014.222
doi: 10.1038/ki.2014.222
pubmed: 24988064
Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS, the IPHR Investigators (2010) Transplantation outcomes in primary hyperoxaluria. Am J Transplant 10:2493–2501. https://doi.org/10.1111/j.1600-6143.2010.03271.x
doi: 10.1111/j.1600-6143.2010.03271.x
pubmed: 20849551
pmcid: 2965313
Cochat P, Rumsby G (2013) Primary hyperoxaluria. N Engl J Med 369:649–658. https://doi.org/10.1056/NEJMra1301564
doi: 10.1056/NEJMra1301564
pubmed: 23944302
Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, Jamieson NV, Kemper MJ, Mandrile G, Marangella M, Picca S, Rumsby G, Salido E, Straub M, van Woerden CS, OxalEurope (2012) Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 27:1729–1736. https://doi.org/10.1093/ndt/gfs078
doi: 10.1093/ndt/gfs078
pubmed: 22547750
Eytan Mor MD, Weismann I (2009) Current treatment for primary hyperoxaluria type 1: When should liver/kidney transplantation be considered. Pediatr Transplant 13:805–807. https://doi.org/10.1111/j.1399-3046.2009.01230.x
doi: 10.1111/j.1399-3046.2009.01230.x
pubmed: 19686442
Gagnadoux MF, Lacaille F, Niaudet P, Revillon Y, Jouvet P, Jan D, Guest G, Charbit M, Broyer M (2001) Long term results of liver-kidney transplantation in children with primary hyperoxaluria. Pediatr Nephrol 16:946–950. https://doi.org/10.1007/s004670100001
doi: 10.1007/s004670100001
pubmed: 11793078
Hoppe B, Langman CB (2003) A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol 18:986–991. https://doi.org/10.1007/s00467-003-1234-x
doi: 10.1007/s00467-003-1234-x
pubmed: 12920626
Frishberg Y, Deschenes G, Cochat P, Magen D, Groothoff J, Hulton SA, Harambat J, Van’t Hoff W, Hoppe B, Lieske JC, McGregor TL, Tamimi N, Haslett P, Talamudupula S, Erbe DV, Milliner DS (2019) A safety and efficacy study of lumasiran, an investigational RNA interference (RNAi) therapeutic, in adult and pediatric patients with primary hyperoxaluria type 1. Eur Urol Suppl 18:e388–e389. https://doi.org/10.1016/s1569-9056(19)30291-x
doi: 10.1016/s1569-9056(19)30291-x
Dicerna™ Presents Additional Data from PHYOX™1 Study of DCR-PHXC in Patients with Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2) (2019).
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100. https://doi.org/10.1371/journal.pmed.1000100
Hootman JM, Driban JB, Sitler MR, Harris KP, Cattano NM (2011) Reliability and validity of three quality rating instruments for systematic reviews of observational studies. Res Synth Methods 2:110–118. https://doi.org/10.1002/jrsm.41
doi: 10.1002/jrsm.41
pubmed: 26061679
Kennelly J (2011) Methodological Approach to Assessing the Evidence. In: Reducing Racial/Ethnic Disparities in Reproductive and Perinatal Outcomes. pp 7-19. https://doi.org/10.1007/978-1-4419-1499-6_2
Cibrik DM, Kaplan B, Arndorfer JA, Meier-Kriesche HU (2002) Renal allograft survival in patients with oxalosis. Transplantation 74:707–710. https://doi.org/10.1097/00007890-200209150-00020
doi: 10.1097/00007890-200209150-00020
pubmed: 12352890
Compagnon P, Metzler P, Samuel D, Camus C, Niaudet P, Durrbach A, Lang P, Azoulay D, Duvoux C, Bayle F, Rivalan J, Merville P, Pascal G, Thervet E, Bensman A, Rostaing L, Deschenes G, Morcet J, Feray C, Boudjema K (2014) Long-term results of combined liver-kidney transplantation for primary hyperoxaluria type 1: the French experience. Liver Transpl 20:1475–1485. https://doi.org/10.1002/lt.24009
doi: 10.1002/lt.24009
pubmed: 25267365
Garrelfs SF, Rumsby G, Peters-Sengers H, Erger F, Groothoff JW, Beck BB, MJS O, Pelle A, Neuhaus T, Adams B, Cochat P, Salido E, Lipkin GW, Hoppe B, Hulton SA, OxalEurope Consortium (2019) Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int 96:1389–1399. https://doi.org/10.1016/j.kint.2019.08.018
doi: 10.1016/j.kint.2019.08.018
pubmed: 31685312
Harambat J, Fargue S, Acquaviva C, Gagnadoux MF, Janssen F, Liutkus A, Mourani C, Macher MA, Abramowicz D, Legendre C, Durrbach A, Tsimaratos M, Nivet H, Girardin E, Schott AM, Rolland MO, Cochat P (2010) Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int 77:443–449. https://doi.org/10.1038/ki.2009.435
doi: 10.1038/ki.2009.435
pubmed: 20016466
Harambat J, van Stralen KJ, Espinosa L, Groothoff JW, Hulton SA, Cerkauskiene R, Schaefer F, Verrina E, Jager KJ, Cochat P (2012) Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol 7:458–465. https://doi.org/10.2215/cjn.07430711
doi: 10.2215/cjn.07430711
pubmed: 22223608
pmcid: 3302673
Jamieson NV (2005) A 20-year experience of combined liver/kidney transplantation for primary hyperoxaluria (PH1): the European PH1 transplant registry experience 1984-2004. Am J Nephrol 25:282–289. https://doi.org/10.1159/000086359
doi: 10.1159/000086359
pubmed: 15961948
Saborio P, Scheinman JI (1999) Transplantation for primary hyperoxaluria in the United States. Kidney Int 56:1094–1100. https://doi.org/10.1046/j.1523-1755.1999.00619.x
doi: 10.1046/j.1523-1755.1999.00619.x
pubmed: 10469379
Xiang J, Chen Z, Xu F, Mei S, Li Z, Zhou J, Dong Y, Gu Y, Huang Z, Hu Z (2020) Outcomes of liver-kidney transplantation in patients with primary hyperoxaluria: an analysis of the scientific registry of transplant recipients database. BMC Gastroenterol 20:208. https://doi.org/10.1186/s12876-020-01349-1
doi: 10.1186/s12876-020-01349-1
pubmed: 32620094
pmcid: 7333252
Al Riyami MS, Al Ghaithi B, Al Hashmi N, Al Kalbani N (2015) Primary hyperoxaluria type 1 in 18 children: genotyping and outcome. Int J Nephrol 2015:634175. https://doi.org/10.1155/2015/634175
doi: 10.1155/2015/634175
pubmed: 25918646
pmcid: 4396551
Binswanger U, Keusch G, Frei D (1986) Kidney transplantation in primary hyperoxaluria of adult patients. Transplant Proc 18(4 SUPPL. 3):14–15
Brinkert F, Ganschow R, Helmke K, Harps E, Fischer L, Nashan B, Hoppe B, Kulke S, Muller-Wiefel DE, Kemper MJ (2009) Transplantation procedures in children with primary hyperoxaluria type 1: outcome and longitudinal growth. Transplantation 87:1415–1421. https://doi.org/10.1097/TP.0b013e3181a27939
doi: 10.1097/TP.0b013e3181a27939
pubmed: 19424045
Broyer M, Jouvet P, Niaudet P, Daudon M, Revillon Y (1996) Management of oxalosis. Kidney Int Suppl 53:S93–S98
pubmed: 8770999
Buscher R, Buscher AK, Cetiner M, Treckmann JW, Paul A, Vester U, Hoyer PF (2015) Combined liver and kidney transplantation and kidney after liver transplantation in children: Indication, postoperative outcome, and long-term results. Pediatr Transplant 19:858–865. https://doi.org/10.1111/petr.12595
doi: 10.1111/petr.12595
pubmed: 26341656
Duclaux-Loras R, Bacchetta J, Berthiller J, Rivet C, Demede D, Javouhey E, Dubois R, Dijoud F, Lachaux A, Badet L, Boillot O, Cochat P (2016) Pediatric combined liver-kidney transplantation: a single-center experience of 18 cases. Pediatr Nephrol 31:1517–1529. https://doi.org/10.1007/s00467-016-3324-6
doi: 10.1007/s00467-016-3324-6
pubmed: 27060059
Ellis SR, Hulton SA, McKiernan PJ, de Ville de Goyet J, Kelly DA (2001) Combined liver-kidney transplantation for primary hyperoxaluria type 1 in young children. Nephrol Dial Transplant 16:348–354. https://doi.org/10.1093/ndt/16.2.348
doi: 10.1093/ndt/16.2.348
pubmed: 11158411
Horoub R, Shamsaeefar A, Dehghani M, Nikoopour H, Entezari M, Moradi A, Kazemi K, Eshraghian A, Nikeghbalian S, Malek-Hosseini SA (2019) Liver Transplant for Primary Hyperoxaluria Type 1: Results of Sequential, Combined Liver and Kidney, and Preemptive Liver Transplant. Exp Clin Transplant. https://doi.org/10.6002/ect.2019.0150
Jacobs C, Rottembourgh J, Reach I, Legrain M (1975) Terminal renal failure due to oxalosis in 14 patients. Proc Eur Dial Transplant Assoc 11:359–366
pubmed: 1105557
Jouvet P, Priqueler L, Gagnadoux MF, Jan D, Beringer A, Lacaille F, Revillon Y, Broyer M, Daudon M (1998) Crystalluria: a clinically useful investigation in children with primary hyperoxaluria post-transplantation. Kidney Int 53:1412–1416. https://doi.org/10.1046/j.1523-1755.1998.00876.x
doi: 10.1046/j.1523-1755.1998.00876.x
pubmed: 9573560
Katz A, Freese D, Danpure CJ, Scheinman JI, Mauer SM (1992) Success of kidney transplantation in oxalosis is unrelated to residual hepatic enzyme activity. Kidney Int 42:1408–1411. https://doi.org/10.1038/ki.1992.434
doi: 10.1038/ki.1992.434
pubmed: 1474773
Kemper MJ, Nolkemper D, Rogiers X, Timmermann K, Sturm E, Malago M, Broelsch CE, Burdelski M, Muller-Wiefel DE (1998) Preemptive liver transplantation in primary hyperoxaluria type 1: timing and preliminary results. J Nephrol 11(Suppl 1):46–48
pubmed: 9604810
Khorsandi SE, Samyn M, Hassan A, Vilca-Melendez H, Waller S, Shroff R, Koffman G, Van't Hoff W, Baker A, Dhawan A, Heaton N (2016) An institutional experience of pre-emptive liver transplantation for pediatric primary hyperoxaluria type 1. Pediatr Transplant 20:523–529. https://doi.org/10.1111/petr.12705
doi: 10.1111/petr.12705
pubmed: 27061278
Kotb MA, Hamza AF, Abd El Kader H, El Monayeri M, Mosallam DS, Ali N, Basanti CWS, Bazaraa H, Abdelrahman H, Nabhan MM, Abd El Baky H, El Sorogy STM, Kamel IEM, Ismail H, Ramadan Y, Abd El Rahman SM, Soliman NA (2019) Combined liver-kidney transplantation for primary hyperoxaluria type I in children: Single Center Experience. Pediatr Transplant 23:e13313. https://doi.org/10.1111/petr.13313
doi: 10.1111/petr.13313
pubmed: 30475440
Lorenz EC, Lieske JC, Seide BM, Meek AM, Olson JB, Bergstralh EJ, Milliner DS (2014) Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant. Am J Transplant 14:1433–1438. https://doi.org/10.1111/ajt.12706
doi: 10.1111/ajt.12706
pubmed: 24797341
pmcid: 4543374
Lorenzo V, Alvarez A, Torres A, Torregrosa V, Hernandez D, Salido E (2006) Presentation and role of transplantation in adult patients with type 1 primary hyperoxaluria and the I244T AGXT mutation: Single-center experience. Kidney Int 70:1115–1119. https://doi.org/10.1038/sj.ki.5001758
doi: 10.1038/sj.ki.5001758
pubmed: 16912707
Malde DJ, Pararajasingam R, Tavakoli A, Campbell B, Riad H, Parrot N, Prasad KR, Augustine T (2011) Transplantation in adults with primary hyperoxaluria: single unit experience and treatment algorithm. Ann Transplant 16:111–117. https://doi.org/10.12659/aot.882227
doi: 10.12659/aot.882227
pubmed: 22210430
Mantel HT, Buis CI, van der Heide JJ, van der Berg AP, Verkade HJ, Haagsma EB, Peeters PM, de Jong KP, Slooff MJ, Porte RJ (2006) Combined liver and kidney transplantation: indications and results at the University Medical Centre Groningen, 1994-2005. Ned Tijdschr Geneeskd 150:2260–2265
pubmed: 17076363
Millan MT, Berquist WE, So SK, Sarwal MM, Wayman KI, Cox KL, Filler G, Salvatierra O Jr, Esquivel CO (2003) One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience. Transplantation 76:1458–1463. https://doi.org/10.1097/01.Tp.0000084203.76110.Ac
doi: 10.1097/01.Tp.0000084203.76110.Ac
pubmed: 14657686
Milliner DS, Wilson DM, Smith LH (1998) Clinical expression and long-term outcomes of primary hyperoxaluria types 1 and 2. J Nephrol 11(Suppl 1):56–59
pubmed: 9604813
Monico CG, Milliner DS (2001) Combined liver-kidney and kidney-alone transplantation in primary hyperoxaluria. Liver Transpl 7:954–963. https://doi.org/10.1053/jlts.2001.28741
doi: 10.1053/jlts.2001.28741
pubmed: 11699031
Narasimhan G, Govil S, Rajalingam R, Venkataraman C, Shanmugam NP, Rela M (2015) Preserving double equipoise in living donor liver-kidney transplantation for primary hyperoxaluria type 1. Liver Transpl 21:1324–1326. https://doi.org/10.1002/lt.24167
doi: 10.1002/lt.24167
pubmed: 25980756
Nolkemper D, Kemper MJ, Burdelski M, Vaismann I, Rogiers X, Broelsch CE, Ganschow R, Muller-Wiefel DE (2000) Long-term results of pre-emptive liver transplantation in primary hyperoxaluria type 1. Pediatr Transplant 4:177–181
doi: 10.1034/j.1399-3046.2000.00107.x
pubmed: 10933316
Ozer A, Aktas H, Bulum B, Emiroglu R (2019) The experience of combined and sequential liver and kidney transplantation from a single living donor in patients with primary hyperoxaluria type 1. Pediatr Transplant 23:e13406. https://doi.org/10.1111/petr.13406
doi: 10.1111/petr.13406
pubmed: 30932299
Perera MT, McKiernan PJ, Sharif K, Milford DV, Lloyd C, Mayer DA, Kelly DA, Mirza DF (2009) Renal function recovery in children undergoing combined liver kidney transplants. Transplantation 87:1584–1589. https://doi.org/10.1097/TP.0b013e3181a4e710
doi: 10.1097/TP.0b013e3181a4e710
pubmed: 19461498
Perera MT, Sharif K, Lloyd C, Foster K, Hulton SA, Mirza DF, McKiernan PJ (2011) Pre-emptive liver transplantation for primary hyperoxaluria (PH-I) arrests long-term renal function deterioration. Nephrol Dial Transplant 26:354–359. https://doi.org/10.1093/ndt/gfq353
doi: 10.1093/ndt/gfq353
pubmed: 20573805
Pratschke J, Steinmuller T, Bechstein WO, Neuhaus R, Tullius SG, Jonas S, Schumacher G, Luck W, Becker M, Neuhaus P (1998) Orthotopic liver transplantation for hepatic associated metabolic disorders. Clin Transpl 12:228–232
Quintero Bernabeu J, Juamperez J, Munoz M, Rodriguez O, Vilalta R, Molino JA, Asensio M, Bilbao I, Ariceta G, Rodrigo C, Charco R (2018) Successful long-term outcome of pediatric liver-kidney transplantation: a single-center study. Pediatr Nephrol 33:351–358. https://doi.org/10.1007/s00467-017-3782-5
doi: 10.1007/s00467-017-3782-5
pubmed: 28842757
Sasaki K, Sakamoto S, Uchida H, Shigeta T, Matsunami M, Kanazawa H, Fukuda A, Nakazawa A, Sato M, Ito S, Horikawa R, Yokoi T, Azuma N, Kasahara M (2015) Two-step transplantation for primary hyperoxaluria: a winning strategy to prevent progression of systemic oxalosis in early onset renal insufficiency cases. Pediatr Transplant 19:E1–E6. https://doi.org/10.1111/petr.12376
doi: 10.1111/petr.12376
pubmed: 25323048
Schmaeschke K, Lezius S, Grabhorn E, Kemper MJ, Brinkert F (2017) Health-related quality of life after combined liver and kidney transplantation in children. Pediatr Transplant 21(4). https://doi.org/10.1111/petr.12902
Shapiro R, Weismann I, Mandel H, Eisenstein B, Ben-Ari Z, Bar-Nathan N, Zehavi I, Dinari G, Mor E (2001) Primary hyperoxaluria type 1: improved outcome with timely liver transplantation: a single-center report of 36 children. Transplantation 72:428–432. https://doi.org/10.1097/00007890-200108150-00012
doi: 10.1097/00007890-200108150-00012
pubmed: 11502971
Watts RW, Morgan SH, Purkiss P, Mansell MA, Baker LR, Brown CB (1988) Timing of renal transplantation in the management of pyridoxine-resistant type I primary hyperoxaluria. Transplantation 45:1143–1145
doi: 10.1097/00007890-198806000-00031
pubmed: 3289157
Kitajima K, Ogawa Y, Miki K, Kai K, Sannomiya A, Iwadoh K, Murakami T, Koyama I, Nakajima I, Fuchinoue S (2017) Longterm renal allograft survival after sequential liver-kidney transplantation from a single living donor. Liver Transpl 23:315–323. https://doi.org/10.1002/lt.24676
doi: 10.1002/lt.24676
pubmed: 27862900
Creput C, Durrbach A, Samuel D, Eschwege P, Amor M, Kriaa F, Kreis H, Benoit G, Bismuth H, Charpentier B (2003) Incidence of renal and liver rejection and patient survival rate following combined liver and kidney transplantation. Am J Transplant 3:348–356
doi: 10.1034/j.1600-6143.2003.00050.x
pubmed: 12614293
Nissel R, Latta K, Gagnadoux MF, Kelly D, Hulton S, Kemper MJ, Ruder H, Soderdahl G, Otte JB, Cochat P, Roquet O, Jamieson NV, Haffner D (2006) Body growth after combined liver-kidney transplantation in children with primary hyperoxaluria type 1. Transplantation 82:48–54. https://doi.org/10.1097/01.tp.0000225831.35143.06
doi: 10.1097/01.tp.0000225831.35143.06
pubmed: 16861941
Watts RW, Morgan SH, Danpure CJ, Purkiss P, Calne RY, Rolles K, Baker LR, Mansell MA, Smith LH, Merion RM, Lucey MR (1991) Combined hepatic and renal transplantation in primary hyperoxaluria type I: clinical report of nine cases. Am J Med 90:179–188
doi: 10.1016/0002-9343(91)90539-A
pubmed: 1996585
Cochat P, Deloraine A, Rotily M, Olive F, Liponski I, Deries N (1995) Epidemiology of primary hyperoxaluria type 1. Societe de Nephrologie and the Societe de Nephrologie Pediatrique. Nephrol Dial Transplant 10(Suppl 8):3–7. https://doi.org/10.1093/ndt/10.supp8.3
doi: 10.1093/ndt/10.supp8.3
pubmed: 8592622
Cochat P, Koch Nogueira PC, Mahmoud MA, Jamieson NV, Scheinman JI, Rolland MO (1999) Primary hyperoxaluria in infants: medical, ethical, and economic issues. J Pediatr 135:746–750. https://doi.org/10.1016/s0022-3476(99)70095-8
doi: 10.1016/s0022-3476(99)70095-8
pubmed: 10586179
Hoppe B, Latta K, von Schnakenburg C, Kemper MJ (2005) Primary hyperoxaluria--the German experience. Am J Nephrol 25:276–281. https://doi.org/10.1159/000086358
doi: 10.1159/000086358
pubmed: 15961947
Watts RW, Danpure CJ, De Pauw L, Toussaint C (1991) Combined liver-kidney and isolated liver transplantations for primary hyperoxaluria type 1: the European experience. The European Study Group on Transplantation in Hyperoxaluria Type 1. Nephrol Dial Transplant 6:502–511. https://doi.org/10.1093/ndt/6.7.502
doi: 10.1093/ndt/6.7.502
pubmed: 1922912
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15273542
pmcid: 1360123
Marcen R, Morales JM, Fernandez-Rodriguez A, Capdevila L, Pallardo L, Plaza JJ, Cubero JJ, Puig JM, Sanchez-Fructuoso A, Arias M, Alperovich G, Seron D (2010) Long-term graft function changes in kidney transplant recipients. NDT Plus 3(Suppl_2):ii2–ii8. https://doi.org/10.1093/ndtplus/sfq063
doi: 10.1093/ndtplus/sfq063
pubmed: 20508857
pmcid: 2875040
Hoyer-Kuhn H, Kohbrok S, Volland R, Franklin J, Hero B, Beck BB, Hoppe B (2014) Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin J Am Soc Nephrol 9:468–477. https://doi.org/10.2215/CJN.06820613
doi: 10.2215/CJN.06820613
pubmed: 24385516
pmcid: 3944765
van Woerden CS, Groothoff JW, Wijburg FA, Annink C, Wanders RJ, Waterham HR (2004) Clinical implications of mutation analysis in primary hyperoxaluria type 1. Kidney Int 66:746–752. https://doi.org/10.1111/j.1523-1755.2004.00796.x
doi: 10.1111/j.1523-1755.2004.00796.x
pubmed: 15253729
Pham TA, Esquivel C (2019) Are two operations better than one? The debate over combined versus sequential liver-kidney transplantation from a single live donor in the treatment of primary hyperoxaluria 1. Pediatr Transplant 23:e13457. https://doi.org/10.1111/petr.13457
doi: 10.1111/petr.13457
pubmed: 31081215
Adam R, Karam V, Cailliez V, JG OG, Mirza D, Cherqui D, Klempnauer J, Salizzoni M, Pratschke J, Jamieson N, Hidalgo E, Paul A, Andujar RL, Lerut J, Fisher L, Boudjema K, Fondevila C, Soubrane O, Bachellier P, Pinna AD, Berlakovich G, Bennet W, Pinzani M, Schemmer P, Zieniewicz K, Romero CJ, De Simone P, Ericzon BG, Schneeberger S, Wigmore SJ, Prous JF, Colledan M, Porte RJ, Yilmaz S, Azoulay D, Pirenne J, Line PD, Trunecka P, Navarro F, Lopez AV, De Carlis L, Pena SR, Kochs E, Duvoux C; all the other 126 contributing centers ( www.eltr.org ) and the European Liver and Intestine Transplant Association (ELITA) (2018) 2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation. Transpl Int 31:1293-1317. https://doi.org/10.1111/tri.13358
Kemper MJ (2005) The role of preemptive liver transplantation in primary hyperoxaluria type 1. Urol Res 33:376–379. https://doi.org/10.1007/s00240-005-0495-1
doi: 10.1007/s00240-005-0495-1
pubmed: 16284878
Wei Y, Royston P (2017) Reconstructing time-to-event data from published Kaplan–Meier curves. Stata J 17:786–802
doi: 10.1177/1536867X1801700402
pubmed: 29398980
pmcid: 5796634
Scott LJ, Keam SJ (2021) Lumasiran: First Approval. Drugs. https://doi.org/10.1007/s40265-020-01463-0
Alnylam Pharmaceuticals Inc (2020) Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients.
Devresse A, Cochat P, Godefroid N, Kanaan N (2020) Transplantation for Primary Hyperoxaluria Type 1: Designing New Strategies in the Era of Promising Therapeutic Perspectives. Kidney Int Rep 5:2136–2145. https://doi.org/10.1016/j.ekir.2020.09.022
doi: 10.1016/j.ekir.2020.09.022
pubmed: 33305106
pmcid: 7710835